Data to include insights from 12 indications
from more than 15 CAR T centers in US and Europe
KYV-101 experience in Rheumatological disease
spans 9 patients, with 7 lupus nephritis and 2 systemic sclerosis
patients
Kyverna to host a press conference on
June 14 at 5pm
CEST
EMERYVILLE, Calif., June 7, 2024
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a
patient-centered, clinical-stage biopharmaceutical company focused
on developing cell therapies for patients suffering from autoimmune
diseases, announced today that it will host a sponsored symposium
to present the largest and most diverse set of data to date from a
cohort of 50 patients treated with the CAR in KYV-101, an
autologous, fully human anti-CD19 CAR T-cell immunotherapy. The
data support the differentiated safety profile of the CAR in
various indications, including a 30-patient data set that spans
>28 day follow-up in various autoimmune disease patients
with early efficacy data. A 12-month follow-up of the first
patient treated with KYV-101 for myasthenia gravis will also be
presented.
The symposium titled "Anti-CD19 CAR T-Cell Therapy in
Rheumatologic Autoimmune Diseases and Beyond" will take place on
June 14, 2024, from 8:15 a.m. to 9:30 a.m. CEST. The symposium will
offer insights on the ongoing clinical trials and named-patient
initiatives from leading experts in rheumatology and neurology,
including:
- Dr. Gerhard Krönke, University of Erlangen-Nuremberg,
Germany
- Dr. Peter A. Merkel,
University of Pennsylvania, USA
- Dr. Richard Furie, Northwell
Health, USA
- Dr. Roberto Caricchio,
University of Massachusetts, USA
- Dr. James Chung, Kyverna
Therapeutics, USA
- Peter Maag, Ph.D., Kyverna
Therapeutics, USA
A press conference will be hosted later in the day
featuring Georg Schett, M.D., vice president of research at the
Friedrich-Alexander-University in Erlangen, Germany, and Peter A.
Merkel, M.D., M.P.H. Both are members of Kyverna's
Scientific Advisory Board.
Additionally, Kyverna will showcase two posters on Wednesday, June 12 focusing on the preclinical
development of KYV-201 - the Company's allogeneic product candidate
- and proteomic markers associated with CAR T therapeutic response
in autoimmune diseases, respectively.
"CAR T-cell therapies are rapidly establishing themselves as the
new North star in the autoimmune disease treatment universe," said
Peter Maag, Ph.D., chief executive
officer of Kyverna. "We are seeing rising interests in
unlocking the full potential of cell therapies in rheumatological
and neurological B cell-driven autoimmune diseases."
Kyverna will also set up an exhibit at EULAR (booth E22-23) to
serve as a meeting point for interested healthcare practitioners
and patient advocates.
About KYV-101
KYV-101 is an autologous, fully human CD19 CAR T-cell product
candidate for use in B cell-driven autoimmune diseases. The CAR in
KYV-101 was designed by the National Institutes of Health (NIH) to
improve tolerability and tested in a 20-patient Phase 1 trial in
oncology. Results were published by the NIH in Nature
Medicine1.
KYV-101 is currently being evaluated in sponsored,
open-label, Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune
disease: rheumatology and neurology.
With 50 patients treated so far with the CAR in KYV-101 in both
oncological and autoimmune conditions at more than 15 locations in
Europe and the U.S., we believe
that the differentiated properties of KYV-101 are critical for the
potential success of CAR T cells as autoimmune disease
therapies.
KYV-101 is also being evaluated in investigator-initiated trials
for multiple indications in multiple geographies.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc.
(Nasdaq: KYTX) is a patient-centered, clinical-stage
biopharmaceutical company focused on developing cell therapies for
patients suffering from autoimmune diseases.
Our lead CAR T-cell therapy candidate, KYV-101 is advancing
through clinical development with sponsored clinical trials across
two broad areas of autoimmune disease: rheumatology and neurology,
including Phase 2 trials for multiple sclerosis and myasthenia
gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing
multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna's pipeline includes next-generation CAR T-cell therapies
in both autologous and allogeneic formats with properties intended
to be well suited for use in B cell-driven autoimmune diseases.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements." The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Forward-looking statements in
this press release include, without limitation, those related to:
the potential of cell therapies in rheumatological and neurological
B cell-driven autoimmune diseases and rising interests related
thereto; Kyverna's goals to develop certain paradigm-shifting
treatment options; Kyverna's beliefs about the differentiated
safety profile and other properties of KYV-101; and Kyverna's
clinical trials. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: uncertainties related to market
conditions, and other factors discussed in the "Risk Factors"
section of Kyverna's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q that Kyverna has filed or may
subsequently file with the U.S. Securities and Exchange Commission.
Any forward-looking statements contained in this press release are
based on the current expectations of Kyverna's management team and
speak only as of the date hereof, and Kyverna specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
For more information, please
visit https://kyvernatx.com.
1. Brudno et al., Nature Medicine 2020;
26:270-280.
Kyverna Media Contact:
Consort Partners for
Kyverna
kyvernatx@consortpartners.com
SOURCE Kyverna Therapeutics